Resveratrol attenuates intermittent hypoxia.induced insulin resistance in rats: Involvement of Sirtuin 1 and the phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT pathway

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 151-158

  Wang, Qiuyan ^a   Sun, Xiaohui ^b   Li, Xiaobin ^b   Dong, Xiang ^b   Li, Peng ^a   Zhao, Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Insulin resistance; Intermittent hypoxia; Obstructive sleep apnea; Resveratrol; Sirtuin 1

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; RESVERATROL; SIRTUIN 1; GLUCOSE BLOOD LEVEL; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTECTIVE AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CHRONIC INTERMITTENT HYPOXIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER INJURY; LIVER PROTECTION; LIVER STRUCTURE; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; ANOXIA; BODY WEIGHT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANIMALIA; RATTUS; RICE STRIPE VIRUS;

ANIMALS; ANOXIA; BLOOD GLUCOSE; BODY WEIGHT; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORTER TYPE 2; INSULIN; INSULIN RESISTANCE; LIVER; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, INSULIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES;

EID: 84916214551     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2762     Document Type: Article

References (42)

1. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 5: 136-143, 2008.
2. Casale M, et al: Obstructive sleep apnea syndrome: from phenotype to genetic basis. Curr Genomics 10: 119-126, 2009.
3. Young T, Palta M, Dempsey J, Skatrud J, Weber S and Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328: 1230-1235, 1993.
4. Tasali E and Ip MS: Obstructive sleep apnea and metabolic syndrome: Alterations in glucose metabolism and infammation. Proc Am Thorac Soc 5: 207-217, 2008.
5. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM and Wilding JP: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 25: 735-741, 2004.
6. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW and Lam KS: Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 165: 670-676, 2002.
7. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE and Sleep Heart Health Study I: Sleep-disordered breathing, glucose intolerance, and insulin resistance: The sleep heart health study. Am J Epidemiol 160: 521-530, 2004.
8. Goodson BL, Wung SF and Archbold KH: Obstructive sleep apnea hypopnea syndrome and metabolic syndrome: a syner-gistic cardiovascular risk factor. J Am Acad Nurse Pract 24: 695-703, 2012.
9. Gao ZH, Yuan RY, Chen KY and Li GP: Obstructive sleep apnea and the metabolic syndrome. Sleep Breath 16: 937-938, 2012.
10. Byberg S, Hansen AL, Christensen DL, Vistisen D, Aadahl M, Linneberg A and Witte DR: Sleep duration and sleep quality are associated differently with alterations of glucose homeostasis. Diabet Med 29: e354-e360, 2012.
11. Van Cauter E: Sleep disturbances and insulin resistance. Diabet Med 28: 1455-1462, 2011.
12. Spiegel K, Knutson K, Leproult R, Tasali E and Van Cauter E: Sleep loss: A novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol 99: 2008-2019, 2005.
13. Finkel T, Deng CX and Mostoslavsky R: Recent progress in the biology and physiology of sirtuins. Nature 460: 587-591, 2009.
14. Chakraborty C and Doss CG: Sirtuins family-recent development as a drug target for aging, metabolism and age related diseases. Curr Drug Targets 14: 666-675, 2013.
15. Pucci B, Villanova L, Sansone L, Pellegrini L, Tafani M, Carpi A, Fini M and Russo MA: Sirtuins: The molecular basis of bene-fcial effects of physical activity. Intern Emerg Med 8 (Suppl 1): S23-S25, 2013.
16. Bagul PK and Banerjee SK: Insulin resistance, oxidative stress and cardiovascular complications: Role of sirtuins. Curr Pharm Des 19: 5663-5677, 2013.
17. Chen YR, Lai YL, Lin SD, Li XT, Fu YC and Xu WC: Sirt1 interacts with metabolic transcriptional factors in the pancreas of insulin-resistant and calorie-restricted rats. Mol Biol Rep 40: 3373-3380, 2013.
18. Jung TW, Lee KT, Lee MW and Ka KH: Sirt1 attenuates palmitate-induced endoplasmic reticulum stress and insulin resistance in hepg2 cells via induction of oxygen-regulated protein 150. Biochem Biophys Res Commun 422: 229-232, 2012.
19. Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O and Deng CX: Hepatic sirt1 defciency in mice impairs mtorc2/akt signaling and results in hyperglycemia, oxidative damage and insulin resistance. J Clin Invest 121: 4477-4490, 2011.
20. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R and Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342, 2006.
21. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P and Auwerx J: Resveratrol improves mitochondrial function and protects against metabolic disease by activating sirt1 and pgc-1alpha. Cell 127: 1109-1122, 2006.
22. Tennen RI, Michishita-Kioi E and Chua KF: Finding a target for resveratrol. Cell 148: 387-389, 2012.
23. Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Franzel B, Tomaschewski J, Aladini F, Becker C, Wolters D and Steegborn C: A molecular mechanism for direct sirtuin activation by resveratrol. PloS One 7: e49761, 2012.
24. Iiyori N, Alonso LC, Li J, Sanders MH, Garcia-Ocana A, O'Doherty RM, Polotsky VY and O'Donnell CP: Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 175: 851-857, 2007.
25. Polotsky VY, Rubin AE, Balbir A, Dean T, Smith PL, Schwartz AR and O'Donnell CP: Intermittent hypoxia causes rem sleep defcits and decreases eeg delta power in nrem sleep in the c57bl/6j mouse. Sleep Med 7: 7-16, 2006.
26. Choi K and Kim YB: Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med 25: 119-129, 2010.
27. Babacanoglu C, Yildirim N, Sadi G, Pektas MB and Akar F: Resveratrol prevents high-fructose corn syrup-induced vascular insulin resistance and dysfunction in rats. Food Chem Toxicol 60: 160-167, 2013.
28. Cheng AS, Cheng YH, Chiou CH and Chang TL: Resveratrol upregulates nrf2 expression to attenuate methylglyoxal-induced insulin resistance in hep g2 cells. J Agric Food Chem 60: 9180-9187, 2012.
29. Bagul PK, Middela H, Matapally S, Padiya R, Bastia T, Madhusudana K, Reddy BR, Chakravarty S and Banerjee SK: Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 66: 260-268, 2012.
30. Chen S, Li J, Zhang Z, Li W, Sun Y, Zhang Q, Feng X and Zhu W: Effects of resveratrol on the amelioration of insulin resistance in kkay mice. Can J Physiol Pharmacol 90: 237-242, 2012.
31. Zheng J, Chen LL, Zhang HH, Hu X, Kong W and Hu D: Resveratrol improves insulin resistance of catch-up growth by increasing mitochondrial complexes and antioxidant function in skeletal muscle. Metabolism 61: 954-965, 2012.
32. Chen LL, Zhang HH, Zheng J, Hu X, Kong W, Hu D, Wang SX and Zhang P: Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation. Metabolism 60: 1598-1609, 2011.
33. Labbé A, Garand C, Cogger VC, Paquet ER, Desbiens M, Le Couteur DG and Lebel M: Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertri-glyceridemia, infammation and life span in a mouse model for Werner syndrome. J Gerontol A Biol Sci Med Sci 66: 264-278, 2011.
34. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B and Sinclair DA: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196, 2003.
35. Yun JM, Chien A, Jialal I and Devaraj S: Resveratrol up-regulates sirt1 and inhibits cellular oxidative stress in the diabetic milieu: Mechanistic insights. J Nutr Biochem 23: 699-705, 2012.
36. Liang F, Kume S and Koya D: Sirt1 and insulin resistance. Nat Rev Endocrinol 5: 367-373, 2009.
37. Zabolotny JM and Kim YB: Silencing insulin resistance through sirt1. Cell Metab 6: 247-249, 2007.
38. Farese RV, Sajan MP and Standaert ML: Insulin-sensitive protein kinases (atypical protein kinase c and protein kinase b/akt): Actions and defects in obesity and type II diabetes. Exp Biol Med (Maywood) 230: 593-605, 2005.
39. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J and Kahn CR: Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 s6 kinase, DNA synthesis and glucose transporter translocation. Mol Cell Biol 14: 4902-4911, 1994.
40. Kim YB, Nikoulina SE, Ciaraldi T P, Henry RR and Kahn BB: Normal insulin-dependent activation of akt/protein kinase b, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104: 733-741, 1999.
41. Bjornholm M, Kawano Y, Lehtihet M and Zierath JR: Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from niddm subjects after in vivo insulin stimulation. Diabetes 46: 524-527, 1997.
42. Frojdo S, Durand C, Molin L, Carey AL, El-Osta A, Kingwell BA, Febbraio MA, Solari F, Vidal H and Pirola L: Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by sirt1. Mol Cell Endocrinol 335: 166-276, 2011.